Effect of human erythropoietin (hEPO) treatment on anemia in ICR-derived glomerulonephritis (ICGN) mice

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

ICR-derived glomerulonephritis (ICGN) mice are a novel inbred strain with hereditary nephrotic syndrome and are thus considered a good animal model of human idiopathic nephrotic syndrome. In the present study, we investigated the effect to erythrocyte production by human erythropoietin (hEPO) treatment in ICGN mice during the early nephrotic stage. Erythrocyte count, hemoglobin concentration and hematocrit value in hEPO-treated (5 U/body/day, for 5 days) ICGN mice were recovered to the levels found in normal ICR mice. In addition, there was no correlation between plasma creatinine level, a marker of renal function, and erythrocyte count after hEPO treatment. Therefore, anemia in progressive parenchymal damage. Copyright © 2005 Japanese Association for Laboratory Animal Science.

Cite

CITATION STYLE

APA

Miyamoto, Y., Kuramitsu-Miyamoto, K., Iwanaga, E., Uchio-Yamada, K., Yamaguchi-Yamada, M., Ogura, A., & Manabe, N. (2005). Effect of human erythropoietin (hEPO) treatment on anemia in ICR-derived glomerulonephritis (ICGN) mice. Experimental Animals, 54(2), 181–184. https://doi.org/10.1538/expanim.54.181

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free